Your English writing platform
Discover LudwigExact(8)
These CT trials are often preceded by nonclinical programs that provide robust efficacy and safety data for the specific CT and specific clinical indication using in vitro and in vivo models that were reasonably justified for the appropriate regulatory agency.
Multiple low-dose spiral computed tomography (CT) trials have been proposed, as proponents predict that small nodules will represent early-stage disease and detecting them will ultimately translate into improvements in outcomes.
Differences were identified in baseline characteristics of patients entered into non-CT phase I studies compared to CT trials.
Previous CT trials used this type of active control condition [ 38] with minimal impact on cognitive outcomes.
More than 90% of the positive tests in CT trials are false positive, that is, the positive predictive value of a positive test is <10%.
Therefore the common assessment pattern in CT trials administering questionnaires only at the day of CT administration is likely to miss time points of high levels of acute side-effects.
Similar(52)
Direct comparison from data in this analysis has been restricted by the imbalance in number of patients receiving CT vs non-CT trials (114 vs 306 patients respectively).
Female gender is also a significant factor for toxicity in non-CT trials.
This retrospective analysis is the first to be reported, that directly considers phase I non-CT trials.
The median age was slightly lower for patients receiving CT drugs (55 vs 58 years; P=0.04, Mann–Whitney U-test), although more patients had a performance status of zero in the non-CT trials (P=0.02, Fisher's exact test).
a AT Alexander Technique, RCT randomised controlled trial, CT controlled trial, BP blood pressure, NF neurofeedback, EMG electromyography.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com